# US 2017/0281762 A1 · Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281762 A1
- Document ID: US20170281762A1
- Status: Published application
- Kind: A1
- Application number: 15/508,441
- Filed: 2015-09-08
- Published: 2017-10-05
- Earliest claimed: 2014-09-10
- Assignees: Novartis AG
- Inventors: Shephard MPOFU; Hanno RICHARDS; Gregory LIGOZIO
- Web page: https://patentgrep.com/patent/US20170281762A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/18: against material from animals or humans
- C07K 16/244: {Interleukins [IL]}
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates to methods, uses, medicaments, pharmaceutical formulations, dosage forms, and kits for inhibiting the progression of structural damage in psoriatic arthritis (PsA) patients using IL-17 antagonists, e.g., IL-17 antibodies and antigen-binding fragments thereof, e.g., secukinumab.

## Claims

### Claim at position 1

-28. (canceled)

### Claim 29

A method of inhibiting the progression of structural damage in a patient having psoriatic arthritis (PsA), comprising selectively administering to the patient about 150 mg-about 300 mg of an 1L-17 antibody by subcutaneous injection with initial dosing at week 0, 1, 2, 3, and 4, followed by dosing every 4 weeks, wherein the patient is selected for treatment based on having had an inadequate response to previous treatment with a TNF alpha antagonist, and wherein:
i) the IL-17 antibody comprises an immunoglobulin VH domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin VL domain comprising the amino acid sequence set forth as SEQ ID NO:10;
ii) the IL-17 antibody comprises an immunoglobulin VH domain comprising the hypervariable regions set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 and an immunoglobulin VL domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6;
iii) the IL-17 antibody comprises an immunoglobulin VH domain comprising the hypervariable regions set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13 and an immunoglobulin VL domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6;
iv) the 1L-17 antibody comprises an immunoglobulin light chain comprising the amino acid sequence set forth as SEQ ID NO:14 and an immunoglobulin heavy chain comprising the amino acid sequence set forth as SEQ ID NO:15; or
v) the IL-17 antibody is secukinumab.

### Claim 30

A method of inhibiting the progression of structural damage in a patient having psoriatic arthritis (PsA), comprising selectively administering to the patient about 150 mg-about 300 mg of an IL-17 antibody by subcutaneous injection with initial dosing at week 0, 1, 2, 3, and 4, followed by dosing every 4 weeks, wherein the patient is selected for treatment based on having concomitant psoriasis, and wherein:
i) the IL-17 antibody comprises an immunoglobulin VH domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin VL domain comprising the amino acid sequence set forth as SEQ ID NO:10;
ii) the IL-17 antibody comprises an immunoglobulin VH domain comprising the hypervariable regions set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 and an immunoglobulin VL domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6;
iii) the IL-17 antibody comprises an immunoglobulin VH domain comprising the hypervariable regions set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13 and an immunoglobulin VL domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6;
iv) the IL-17 antibody comprises an immunoglobulin light chain comprising the amino acid sequence set forth as SEQ ID NO:14 and an immunoglobulin heavy chain comprising the amino acid sequence set forth as SEQ ID NO:15; or
v) the IL-17 antibody is secukinumab.

### Claim 31

A method of inhibiting the progression of structural damage in a patient having psoriatic arthritis (PsA), comprising selectively administering to the patient about 150 mg-about 300 mg of an IL-17 antibody by subcutaneous injection with initial dosing at week 0, 1, 2, 3, and 4, followed by dosing every 4 weeks, wherein the patient is selected for treatment based on being TNF nïave and not having concomitant psoriasis, and wherein:
i) the IL-17 antibody comprises an immunoglobulin VH domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin VL domain comprising the amino acid sequence set forth as SEQ ID NO:10;
ii) the IL-17 antibody comprises an immunoglobulin VH domain comprising the hypervariable regions set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 and an immunoglobulin VL domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6;
iii) the IL-17 antibody comprises an immunoglobulin VH domain comprising the hypervariable regions set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13 and an immunoglobulin VL domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6;
iv) the IL-17 antibody comprises an immunoglobulin light chain comprising the amino acid sequence set forth as SEQ ID NO:14 and an immunoglobulin heavy chain comprising the amino acid sequence set forth as SEQ ID NO:15; or
v) the IL-17 antibody is secukinumab.

### Claim 32 (depends on 29)

The method according to claim 29, wherein the patient has concomitant moderate-to severe plaque psoriasis.

### Claim 33 (depends on 30)

The method according to claim 30, wherein the patient has concomitant moderate-to severe plaque psoriasis.

### Claim 34 (depends on 29)

The method according to claim 29, wherein the patient is administered about 300 mg of the IL-17 antibody.

### Claim 35 (depends on 30)

The method according to claim 30, wherein the patient is administered about 150 mg of the IL-17 antibody.

### Claim 36 (depends on 29)

The method according to claim 29, wherein the IL-17 antibody is administered concomitantly with methotrexate.

### Claim 37 (depends on 30)

The method according to claim 30, wherein the IL-17 antibody is administered concomitantly with methotrexate.

### Claim 38 (depends on 29)

The method according to claim 29, wherein the IL-17 antibody is administered without concomitant administration of methotrexate.

### Claim 39 (depends on 29)

The method according to claim 29, wherein the progression of erosion, joint space narrowing, pencil-in-cup phenomena, joint widening, joint narrowing, subluxation, bony proliferation, osteolysis, or ankylosis is inhibited.

### Claim 40 (depends on 30)

The method according to claim 30, wherein the progression of erosion, joint space narrowing, pencil-in-cup phenomena, joint widening, joint narrowing, subluxation, bony proliferation, osteolysis, or ankylosis is inhibited.

### Claim 41 (depends on 29)

The method according to claim 29, wherein the progression of erosion, joint space narrowing, pencil-in-cup phenomena, joint widening, joint narrowing, subluxation, bony proliferation, osteolysis, or ankylosis is inhibited.

### Claim 42 (depends on 31)

The method according to claim 31, wherein following administration of the IL-17 antibody, the patient experiences:
a) a change from baseline in the van der Heijde psoriatic arthritis-modified total Sharp score (mTSS) of ≦0.5;
b) a change from baseline in erosion score of ≦0.3; and/or
c) a change from baseline in joint space narrowing (JSN) score of ≦0.2.

### Claim 43 (depends on 30)

The method according to claim 30, wherein following administration of the IL-17 antibody, the patient experiences:
a) a change from baseline in the van der Heijde psoriatic arthritis-modified total Sharp score (mTSS) of ≦0.5;
b) a change from baseline in erosion score of ≦0.3; and/or
c) a change from baseline in joint space narrowing (JSN) score of ≦0.2.

### Claim 44 (depends on 31)

The method according to claim 31, wherein following administration of the 1L-17 antibody, the patient experiences:
a) a change from baseline in the van der Heijde psoriatic arthritis-modified total Sharp score (mTSS) of ≦0.5;
b) a change from baseline in erosion score of ≦0.3; and/or
c) a change from baseline in joint space narrowing (JSN) score of ≦0.2.

### Claim 45 (depends on 29)

The method according to claim 29, wherein the IL-17 antibody is secukinumab.

### Claim 46 (depends on 30)

The method according to claim 30, wherein the IL-17 antibody is secukinumab.

### Claim 47 (depends on 31)

The method according to claim 31, wherein the IL-17 antibody is secukinumab.

### Claim 48

A method of inhibiting the progression of structural damage in a patient having psoriatic arthritis (PsA), administering the patient about 150 mg-about 300 mg of secukinumab by subcutaneous injection every 4 weeks.
